Format

Send to

Choose Destination
Nat Rev Immunol. 2015 Apr;15(4):255-63. doi: 10.1038/nri3813. Epub 2015 Mar 13.

Advancing host-directed therapy for tuberculosis.

Author information

1
Aurum Institute, Johannesburg 2193, South Africa.
2
Division of AIDS, National Institutes of Health, Bethesda, Maryland 20852, USA.

Abstract

Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection. Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment duration, prevent resistance and reduce lung injury by promoting autophagy, antimicrobial peptide production and other macrophage effector mechanisms, as well as by modifying specific mechanisms that cause lung inflammation and matrix destruction. The range of candidates is broad, including several agents approved for other clinical indications that are ready for evaluation in Phase II clinical trials. The promise of new and existing host-directed therapies that could accelerate response and improve tuberculosis treatment outcomes is discussed in this Opinion article.

PMID:
25765201
DOI:
10.1038/nri3813
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center